2.12

2.93% -0.10

Tenaya Therapeutics Inc (TNYA)

Overview News Price History Option Chain Financials Discussions Forecast

Tenaya Therapeutics Inc stock is traded at $2.12, with a volume of 818.23K. It is down -2.93% in the last 24 hours and up +12.24% over the past month. Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Previous Close:

$2.22

Open:

$2.24

24h Volume:

818.23K

Relative Volume:

0.42

Market Cap:

$186.96M

Revenue:

Net Income/Loss:

$-117.23M

P/E Ratio:

-0.9507

EPS:

-2.23

Net Cash Flow:

$-95.25M

1W Performance:

+6.68%

1M Performance:

+12.24%

6M Performance:

-48.44%

1Y Performance:

+19.06%

1-Day Range:

$2.12

$2.24

1-Week Range:

$1.91

$2.51

52-Week Range:

$1.61

$7.01

Tenaya Therapeutics Inc Stock (TNYA) Company Profile

Name

Tenaya Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

415-865-2066

Address

171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO

Employee

140

Twitter

Next Earnings Date

Latest SEC Filings

TNYA's Discussions on Twitter

Compare TNYA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNYA	2.145	186.96M	0	-117.23M	-95.25M	-2.23
VRTX	446.42	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	739.53	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	587.24	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.48	24.49B	3.30B	-501.07M	1.03B	11.54

Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-15-22	Initiated	H.C. Wainwright	Buy

Tenaya Therapeutics Inc Stock (TNYA) Latest News

Nov 19, 2024

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Nov 19, 2024

Tenaya Therapeutics Issues Stock Options to New Employees at $1.97 Per Share | TNYA Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

Tenaya Therapeutics SVP sells $4,786 in stock - Investing.com

Nov 18, 2024

Nov 15, 2024

RA Capital Management's Strategic Acquisition in Tenaya Therapeu - GuruFocus.com

Nov 15, 2024

Nov 11, 2024

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) large institutional owners must be happy as stock continues to impress, up 42% over the past week - Simply Wall St

Nov 10, 2024

Nov 07, 2024

Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan Capital - MarketBeat

Nov 07, 2024

Nov 06, 2024

Latham Group, Inc. to Participate in the Baird 2024 Global Industrial Conference - The Manila Times

Nov 06, 2024

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 06, 2024

Nov 05, 2024

abrdn plc Invests $1.06 Million in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat

Nov 05, 2024

Nov 04, 2024

BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com

Nov 04, 2024

Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com

Nov 04, 2024

Nov 03, 2024

Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance

Nov 03, 2024

Nov 01, 2024

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Oct 31, 2024

Oct 30, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Oct 30, 2024

Oct 19, 2024

Piper Sandler raises confidence in Tenaya Therapeutics stock ahead of December data, reiterates Overweight rating - Investing.com Australia

Oct 19, 2024

Oct 18, 2024

Tenaya shares retain stock target, buy rating on safety milestone - Investing.com

Oct 18, 2024

Tenaya shares hold buy rating, positive outlook on trial progress - Investing.com

Oct 18, 2024

Tenaya Therapeutics' (TNYA) "Buy" Rating Reiterated at Canaccord Genuity Group - MarketBeat

Oct 18, 2024

Leerink sees Tenaya's trial update as positive, maintains price target By Investing.com - Investing.com UK

Oct 18, 2024

Tenaya stock undervalued despite strong Ph1 safety update, says Canaccord - Investing.com

Oct 18, 2024

Tenaya (TNYA) Experiences Notable Stock Increase Following Key Update - Stocks Telegraph

Oct 18, 2024

Tenaya shares hold buy rating, positive outlook on trial progress By Investing.com - Investing.com UK

Oct 18, 2024

Oct 17, 2024

Tenaya advances gene therapy trial for heart condition - Investing.com

Oct 17, 2024

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - GlobeNewswire

Oct 17, 2024

Oct 10, 2024

SVP, Accounting and Fin. Ops. Saito Chihiro sold 2,363 shares of Tenaya Therapeutics Inc [TNYA] - Knox Daily

Oct 10, 2024

Oct 09, 2024

Tenaya Therapeutics stock hits 52-week low at $1.63 By Investing.com - Investing.com Canada

Oct 09, 2024

Oct 08, 2024

Technical analysis of Tenaya Therapeutics Inc (TNYA) stock chart patterns - US Post News

Oct 08, 2024

Oct 07, 2024

A Closer Look at Tenaya Therapeutics Inc (TNYA) Stock Gains - The InvestChronicle

Oct 07, 2024

Oct 05, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Brokerages - MarketBeat

Oct 05, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of “Buy” by Brokerages - Defense World

Oct 05, 2024

Oct 04, 2024

Hypertrophic Cardiomyopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing - Barchart

Oct 04, 2024

Oct 03, 2024

Charting the Course: Tenaya Therapeutics Inc’s TNYA Stock Prospects - The InvestChronicle

Oct 03, 2024